A5025416634- RNA modifications and cancer
- Fibroblast Growth Factor Research
- RNA regulation and disease
- Gastric Cancer Management and Outcomes
- Cancer-related molecular mechanisms research
- Medical Imaging and Pathology Studies
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Immune cells in cancer
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Erythropoietin and Anemia Treatment
National Cancer Centre Singapore
2016-2025
Duke-NUS Medical School
2020-2025
National University of Singapore
2020-2025
Australian Water Quality Centre
2025
Indiana University Bloomington
2023-2024
Northern Health
2023-2024
Royal Marsden NHS Foundation Trust
2013
Institute of Cancer Research
2013
SUNY Downstate Health Sciences University
2013
Rosalind Franklin University of Medicine and Science
2011
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, treatment and follow-up gastric cancer (GC) was published in 2016, covered management local, locoregional, locally advanced metastatic disease. At ESMO Asia Meeting November 2017 it decided by both Japanese (JSMO) to convene a special guidelines meeting immediately after JSMO Annual 2018. aim adapt 2016 take into account ethnic differences associated with GC Asian patients....
•This article provides ESMO recommendations adapted for the treatment of GC in Asian patients.•It outlines clinical diagnosis, staging, management, and follow-up patients with GC.•Applicability to availability/reimbursement certain tests treatments is described.•The aim encourage evidence-based medicine improve access state-of-the-art cancer care. The European Society Medical Oncology (ESMO) Clinical Practice Guidelines gastric (GC), published late 2022 updated Gastric Cancer Living...
Peritoneal metastasis (PM) in gastric cancer (GC) is associated with poor prognosis and significant morbidity. We sought to understand the genomic, transcriptomic, tumor microenvironment (TME) features that contribute peritoneal organotropism GC.
Abstract Circulating tumour DNA (ctDNA) has the potential to be a specific biomarker for monitoring of tumours in patients with colorectal cancer (CRC). Here, our aim was develop personalised surveillance strategy monitor clinical course CRC after surgery. We developed patient-specific ctDNA assays based on multiplexed detection somatic mutations identified from patient primary tumours, and applied them detect 44 patients, analysing total 260 plasma samples. found that correlated events – it...
High pressure and temperature (PT) experimental charges are valuable systems made of minerals, often with quenched melt, and/or a fluid. They synthesized to inform petrological solid-state, melt-forming fluid-assisted processes occurring deep within the Earth. Here we explored utility phase mapping for analysis high PT charges. We compared maps obtained automated mineralogy software scanning-electron-microscopes developed an open-source workflow. This generates from combined...
High pressure and temperature (PT) experimental charges are valuable systems composed of minerals, often with quenched melt and/or fluid, synthesized to inform petrological processes deep within Earth. We explored the utility phase mapping for analysis 5 GPa partial melting experiments peridotite. further developed an open-source software workflow generate maps, which is scanning electron microscope (SEM) instrument agnostic. Phase maps were constructed offline, combining high-quality...
Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently expressed in several cancers. Here we show that PRL3-zumab inhibits PRL3+ cells vivo, but not vitro. PRL3 antigens are detected on the cell surface and outer exosomal membranes, implying 'inside-out' externalization of PRL3. a manner consistent classical antibody-dependent cell-mediated...
4590 Background: Nivolumab (N) and Y90-radioembolization (RE) are both therapeutic options in advanced hepatocellular carcinoma (aHCC). Increasing evidence suggests that radiotherapy synergizes with immune checkpoint inhibitors to augment anti-tumour effects. Methods: Eligible Child-Pugh A aHCC patients (pts) were treated Y90-RE followed by N 240mg, 21 days after every 2 weeks thereafter. Pre- on-treatment tumor biopsies together circulating biomarkers obtained. Primary end-point was overall...
IntroductionRET rearrangements are an emerging targetable oncogenic fusion driver in NSCLC. However, the natural history of disease and activity different classes systemic therapy remain to be defined. Furthermore, molecular testing for RET is not yet routine, optimal method unclear. We present a comparative analysis profiling with fluorescence situ hybridization (FISH) or next-generation sequencing (NGS) treatment outcomes.MethodsThis study was retrospective patients treated at National...
3603 Background: Debio 1347 is a selective oral inhibitor of FGFR 1-3 tyrosine kinases. It exhibited high antitumor activity in vitro and vivo tumor models with FGFR1-3 gene fusions. Here we report the results expansion portion Phase 1 study advanced solid tumors patients (pts) harboring an fusion. Methods: Pts refractory fusion were enrolled. Based on from dose escalation portion, pts received Debio1347 80 mg once daily (qd) 28-day cycles. Pharmacokinetics (PK) pharmacodynamics evaluated....
Purpose: Fuchs endothelial corneal dystrophy (FECD) is a progressive blinding disorder, characterized by increased excrescences (guttae), cell loss, and edema. These symptoms are hypothesized to be caused changes in the extracellular matrix (ECM) mitochondrial dysfunction endothelium. Despite this clinical biological relevance, comprehensive animal model that recapitulates all major disease characteristics currently unavailable. In study, we develop such improve our understanding of...
2584 Background: The Wnt signalling pathway is involved in cellular proliferation, differentiation, migration and implicated stem cell function several cancers. ETC-159 a selective small molecule inhibitor of porcupine, an enzyme required for palmitoylation secretion all ligands. In preclinical studies, induced tumour regression patient-derived xenograft models. Methods: Open-label, multi-centre study to determine safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics (PD) given...
This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor FGFR1-3, in patients with solid tumors harboring a functional FGFR1-3 fusion.
Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) is a standard of care for patients with locally advanced gastro-oesophageal adenocarcinoma (GEA) in Western guidelines, but its use limited Asian patients. We report outcomes from single centre perioperative concomitant granulocyte colony-stimulating factor (GCSF) prophylaxis.
Purpose: The oxaliplatin plus S-1 and cisplatin regimens are interchangeably used in the management of advanced gastric cancer. previously reported G-intestinal (G1) G-diffuse (G2) intrinsic gene expression signatures showed promise for stratifying patients according to their tumor sensitivity or cisplatin.Experimental Design: proof-of-concept, multicenter, open-label phase II "3G" trial was done prospectively evaluate feasibility efficacy using genomic classifiers tailor treatment Patients'...
Abstract Background Metastatic gastric cancer has a poor prognosis. We aim to study how clinical features and prognosis differs between different metastatic sites, identify prognostic factors for overall survival. Methods retrospectively reviewed patients with adenocarcinoma managed at tertiary referral center over 5‐year period. divided our cohort into three groups based on the site(s) of metastasis presentation—peritoneal only (P), distant (D), peritoneal metastases (PD). Results studied...
65 Background: Trastuzumab (T) + chemo is standard first-line therapy (tx) for HER2+ gastroesophageal adenocarcinoma (GEA) pts, though progression ensues in 6-8 months. The approved second-line tx ramucirumab +/- paclitaxel (R+PAC). Pts with GC are less responsive to R+PAC than junction (GEJ) particular GC, and no anti-HER2 agents post-T setting. We report results of combination M+P pts describe a biological rationale this population. M an mAb Fc optimized enhanced binding activating...
Background: Cholangiocarcinoma (CCA), an aggressive epithelial neoplasm of biliary tract, presents limited treatment options and poor overall survival. Aberrant fibroblast growth factor receptor (FGFR) signaling has been implicated in CCA carcinogenesis especially intrahepatic cholangiocarcinoma (iCCA). Debio 1347 is orally available selective FGFRi with potent antitumor effect preclinical models cancer bearing FGFR alterations. showed encouraging preliminary clinical activity manageable...